USPH
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
U.S. Physical Therapy, Inc.
- Nom
- U.S. Physical Therapy, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NYSE
- Capitalisation
- $1.3B
- Employés
- 6,374
- PDG
- Christopher J. Reading
- Site web
- https://www.usph.com
- Marché
- AHCOASTHCNMDGDRXHCSGKMTS
U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal conditions, recovery from sports-related trauma, proactive health measures, assistance for workers recovering from injuries, and care for neurological conditions. The company's business is divided into two primary divisions: Physical Therapy Operations and Industrial Injury Prevention Services. Within its industrial segment, it provides specialized services like on-site injury avoidance and recovery programs, strategies for enhancing physical performance, pre-employment screening tests, assessments of an individual's work capacity, and workplace ergonomic reviews. These offerings are delivered by licensed physical therapists and expert certified athletic trainers to a diverse clientele, including Fortune 500 corporations, insurance providers, and their associated contractors. By the end of 2021, specifically December 31st, the company had established 591 operational clinics across 39 states, in addition to overseeing 35 other physical therapy sites. Established in 1990, the company maintains its headquarters in Houston, Texas.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 6 titres (~474 USD)
- Insiders
- Minan Peter Francis
- Total bought
-
$474
Avg buy (VWAP, 90d window) $77.23 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-11
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Minan Peter Francis | Buy · P | 5 | $79.00 | $416 | Form 4 |
| 2026-06-12 | Minan Peter Francis | Buy · P | 1 | $66.50 | $58 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-07-16 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-15 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-16 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-20 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-17 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-01-29 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2024-10-17 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-09-16 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-05-24 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
USPH presents a moderate earnings catalyst (score 60, confidence 0.62) supported by revenue growth and institutional interest from BlackRock, but the weak financial health (liquidity 40, fundamentals trend 35) severely…
The first sentence of the analysis written for USPH on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.01 · operating margin 10%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 20.1% | 18.5% | 20.1% | 20.3% | 23.7% | |
| Ebit Margin | 11.2% | 10.2% | 9.7% | 11.1% | 15.0% | |
| Ebitda Margin | 14.0% | 12.9% | 12.3% | 13.8% | 17.3% | |
| Operating Profit Margin | 10.3% | 9.4% | 8.6% | 10.3% | 14.3% | |
| Pretax Profit Margin | 10.0% | 9.0% | 8.2% | 10.0% | 14.8% | |
| Continuous Operations Profit Margin | 7.4% | 6.8% | 6.2% | 7.8% | 11.7% | |
| Net Profit Margin | 1.9% | 3.9% | 2.4% | 5.1% | 5.6% | |
| Bottom Line Profit Margin | 2.8% | 4.1% | 3.0% | 5.3% | 6.3% | |
| Current Ratio | 1.007 | 1.183 | 2.284 | 1.302 | 1.140 | |
| Quick Ratio | 1.007 | 1.183 | 2.284 | 1.302 | 1.140 | |
| Solvency Ratio | 0.086 | 0.111 | 0.088 | 0.115 | 0.133 | |
| Cash Ratio | 0.256 | 0.356 | 1.496 | 0.370 | 0.342 | |
| Price To Earnings Ratio | 54.993 | 48.212 | 72.766 | 24.260 | 21.281 | |
| Price To Earnings Growth Ratio | -2.409 | 1.102 | -1.180 | -0.947 | 2.176 | |
| Forward Price To Earnings Growth Ratio | -2.409 | 1.102 | -1.180 | -0.947 | 2.176 | |
| Price To Earnings Diluted Ratio | 54.993 | 48.212 | 72.766 | 24.260 | 21.281 | |
| Price To Earnings Diluted Growth Ratio | -2.409 | 1.102 | -1.180 | -0.947 | 2.176 | |
| Price To Book Ratio | 2.487 | 2.733 | 2.775 | 3.332 | 4.169 | |
| Price To Sales Ratio | 1.517 | 1.991 | 2.185 | 1.902 | 2.490 | |
| Price To Free Cash Flow Ratio | 19.431 | 20.323 | 18.181 | 20.923 | 18.069 | |
| Price To Operating Cash Flow Ratio | 15.788 | 17.832 | 16.120 | 17.975 | 16.130 | |
| Debt To Assets Ratio | 0.354 | 0.253 | 0.259 | 0.344 | 0.298 | |
| Debt To Equity Ratio | 0.894 | 0.604 | 0.543 | 0.935 | 0.755 | |
| Debt To Capital Ratio | 0.472 | 0.376 | 0.352 | 0.483 | 0.430 | |
| Long Term Debt To Capital Ratio | 0.356 | 0.226 | 0.226 | 0.358 | 0.285 | |
| Financial Leverage Ratio | 2.527 | 2.388 | 2.094 | 2.717 | 2.535 | |
| Working Capital Turnover Ratio | 70.201 | 8.805 | 7.706 | 29.531 | 169.848 | |
| Operating Cash Flow Ratio | 0.540 | 0.644 | 0.802 | 0.685 | 0.915 | |
| Operating Cash Flow Sales Ratio | 0.096 | 0.112 | 0.136 | 0.106 | 0.154 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.813 | 0.877 | 0.887 | 0.859 | 0.893 | |
| Debt Service Coverage Ratio | 1.462 | 3.802 | 3.661 | 4.686 | 39.761 | |
| Interest Coverage Ratio | 8.503 | 7.887 | 5.596 | 9.829 | 74.999 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.443 | 6.813 | 10.659 | 7.445 | 92.055 | |
| Operating Cash Flow Coverage Ratio | 0.176 | 0.254 | 0.317 | 0.198 | 0.343 | |
| Capital Expenditure Coverage Ratio | 5.334 | 8.158 | 8.821 | 7.097 | 9.317 | |
| Dividend Paid And Capex Coverage Ratio | 1.812 | 2.098 | 2.453 | 1.980 | 2.833 | |
| Dividend Payout Ratio | 1.817 | 1.003 | 1.644 | 0.754 | 0.675 | |
| Enterprise Value Multiple | 14.364 | 18.298 | 19.190 | 17.294 | 16.644 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 20.2% | ▲1.7% | ▼-0.4% |
| Ebit Margin | 11.2% | ▲1.0% | ▼-0.2% |
| Ebitda Margin | 14.0% | ▲1.1% | ▼-0.0% |
| Operating Profit Margin | 10.3% | ▲0.9% | ▼-0.3% |
| Pretax Profit Margin | 10.0% | ▲1.0% | ▼-0.4% |
| Continuous Operations Profit Margin | 7.4% | ▲0.6% | ▼-0.6% |
| Net Profit Margin | 1.9% | ▼-2.0% | ▼-1.9% |
| Bottom Line Profit Margin | 2.8% | ▼-1.4% | ▼-1.5% |
| Current Ratio | 1.007 | ▼-0.176 | ▼-0.376 |
| Quick Ratio | 1.007 | ▼-0.176 | ▼-0.376 |
| Solvency Ratio | 0.086 | ▼-0.024 | ▼-0.020 |
| Cash Ratio | 0.256 | ▼-0.100 | ▼-0.308 |
| Price To Earnings Ratio | 54.993 | ▲6.781 | ▲10.691 |
| Price To Earnings Growth Ratio | -2.409 | ▼-3.511 | ▼-2.158 |
| Forward Price To Earnings Growth Ratio | -2.409 | ▼-3.511 | ▼-2.158 |
| Price To Earnings Diluted Ratio | 54.993 | ▲6.781 | ▲10.691 |
| Price To Earnings Diluted Growth Ratio | -2.409 | ▼-3.511 | ▼-2.158 |
| Price To Book Ratio | 2.487 | ▼-0.246 | ▼-0.612 |
| Price To Sales Ratio | 1.517 | ▼-0.473 | ▼-0.500 |
| Price To Free Cash Flow Ratio | 19.431 | ▼-0.892 | ▲0.045 |
| Price To Operating Cash Flow Ratio | 15.788 | ▼-2.044 | ▼-0.981 |
| Debt To Assets Ratio | 0.354 | ▲0.101 | ▲0.052 |
| Debt To Equity Ratio | 0.894 | ▲0.290 | ▲0.147 |
| Debt To Capital Ratio | 0.472 | ▲0.095 | ▲0.049 |
| Long Term Debt To Capital Ratio | 0.356 | ▲0.130 | ▲0.066 |
| Financial Leverage Ratio | 2.527 | ▲0.139 | ▲0.075 |
| Working Capital Turnover Ratio | 70.201 | ▲61.396 | ▲12.983 |
| Operating Cash Flow Ratio | 0.540 | ▼-0.105 | ▼-0.177 |
| Operating Cash Flow Sales Ratio | 0.096 | ▼-0.015 | ▼-0.025 |
| Free Cash Flow Operating Cash Flow Ratio | 0.812 | ▼-0.065 | ▼-0.053 |
| Debt Service Coverage Ratio | 1.462 | ▼-2.340 | ▼-9.213 |
| Interest Coverage Ratio | 8.503 | ▲0.617 | ▼-12.860 |
| Short Term Operating Cash Flow Coverage Ratio | 1.444 | ▼-5.370 | ▼-22.240 |
| Operating Cash Flow Coverage Ratio | 0.176 | ▼-0.077 | ▼-0.081 |
| Capital Expenditure Coverage Ratio | 5.334 | ▼-2.824 | ▼-2.411 |
| Dividend Paid And Capex Coverage Ratio | 1.812 | ▼-0.286 | ▼-0.423 |
| Dividend Payout Ratio | 1.817 | ▲0.814 | ▲0.638 |
| Enterprise Value Multiple | 14.364 | ▼-3.934 | ▼-2.794 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.19B | $1.34B | $1.32B | $1.05B | $1.23B | |
| Enterprise value | $1.58B | $1.59B | $1.43B | $1.32B | $1.43B | |
| EV / Sales | 2.02x | 2.37x | 2.36x | 2.38x | 2.88x | |
| EV / Op. cash flow | 20.99x | 21.22x | 17.41x | 22.48x | 18.68x | |
| EV / Free cash flow | 25.83x | 24.18x | 19.64x | 26.17x | 20.92x | |
| EV / EBITDA | 14.36x | 18.30x | 19.19x | 17.29x | 16.64x | |
| Net debt / EBITDA | 3.56x | 2.92x | 1.42x | 3.47x | 2.27x | |
| Current ratio | 1.01x | 1.18x | 2.28x | 1.30x | 1.14x | |
| Income quality | 1.29x | 1.64x | 2.20x | 1.35x | 1.32x | |
| Graham number | $26 | $36 | $28 | $35 | $33 | |
| Graham net-net | -$22 | -$20 | -$10 | -$22 | -$17 | |
| Tax burden | 19.4% | 43.9% | 29.7% | 50.9% | 38.0% | |
| Interest burden | 89.2% | 88.3% | 84.1% | 90.6% | 98.7% | |
| Working capital | $950K | $21.3M | $131.2M | $25.8M | $11.7M | |
| Invested capital | $1.14B | $1.03B | $880.0M | $756.4M | $652.2M | |
| Return on assets | 1.3% | 2.3% | 1.5% | 3.3% | 3.7% | |
| Operating ROA | 6.8% | 5.8% | 5.6% | 7.1% | 10.5% | |
| Return on tangible assets | 4.4% | 8.2% | 3.9% | 11.1% | 12.2% | |
| Return on equity | 3.2% | 5.4% | 3.1% | 9.0% | 9.4% | |
| Return on invested capital | 5.4% | 4.3% | 4.2% | 5.4% | 8.0% | |
| Return on capital employed | 7.6% | 6.0% | 5.8% | 7.4% | 10.6% | |
| Earnings yield | 1.3% | 2.0% | 1.1% | 2.7% | 2.3% | |
| Free cash flow yield | 5.1% | 4.9% | 5.5% | 4.8% | 5.5% | |
| Capex / Op. cash flow | 18.7% | 12.3% | 11.3% | 14.1% | 10.7% | |
| Capex / Depreciation | 62.8% | 49.2% | 59.2% | 55.9% | 70.8% | |
| Capex / Sales | 1.8% | 1.4% | 1.5% | 1.5% | 1.7% | |
| SG&A / Sales | 0.0% | 8.7% | 0.0% | 8.3% | 9.4% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.1% | 1.2% | 1.2% | 1.3% | 1.6% | |
| Intangibles / Total assets | 71.9% | 72.5% | 62.1% | 70.3% | 69.5% | |
| Days sales outstanding | 41d | 47d | 42d | 46d | 46d | |
| Days payables outstanding | 4d | 4d | 3d | 5d | 6d | |
| Operating cycle | 41d | 47d | 42d | 46d | 46d | |
| Cash conversion cycle | 38d | 43d | 39d | 40d | 40d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-21 U.S. Physical Therapy Announces the Appointment of New Board Member Myra Davis HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that its Board of Directors (the “Board”) approved the appointment of Ms. Myra Davis to serve as a member of the Board, effective October 1, 2026. Myra Davis currently serves as the Executive Vice President and Chief Information Innovation Officer at Texas Childr.
- 2026-08-31 Freestone Grove Partners LP Makes New Investment in U.S. Physical Therapy, Inc. $USPH Freestone Grove Partners LP acquired a new stake in shares of U.S. Physical Therapy, Inc. (NYSE: USPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 9,969 shares of the company''s stock, valued at approximately $685,000. Freestone Grove Partners LP owned 0.07%
- 2026-08-29 BlackRock Inc. Invests $155.50 Million in U.S. Physical Therapy, Inc. $USPH BlackRock Inc. bought a new stake in U.S. Physical Therapy, Inc. (NYSE: USPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,264,202 shares of the company''s stock, valued at approximately $155,505,000. BlackRock Inc. owned about 14.88% of U.S. Physical Therapy at
- 2026-08-29 U.S. Physical Therapy Bets on Hospital Alliances to Drive Visits, Reimbursement U.S. Physical Therapy (NYSE: USPH) is pursuing growth through clinic openings, acquisitions and a newer hospital-alliance strategy that Chief Executive Officer Chris Reading said could expand patient volumes and improve reimbursement. Speaking at an investor event, Reading said the company operates in 45 states with just under 800 locations focused primarily on orthopedic and musculoskeletal care,
- 2026-08-27 U.S. Physical Therapy Bets on Hospital Alliances to Drive Visits, Reimbursement U.S. Physical Therapy NYSE: USPH is pursuing growth through clinic openings, acquisitions and a newer hospital-alliance strategy that Chief Executive Officer Chris Reading said could expand patient volumes and improve reimbursement.
- 2026-08-27 U.S. Physical Therapy Presented at the 17th Annual Midwest Ideas Conference HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chairman and Chief Executive Officer, presented at the 17th Annual Midwest Ideas Conference held on August 26, 2026. The presentation included a discussion of the overall operating environment in healthcare, the Company''s key initiatives and a.
- 2026-08-14 U.S. Physical Therapy Announces CFO HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), today announced that Nchacha Etta will serve as the Company''s Executive Vice President and Chief Financial Officer, effective as of September 1, 2026. Jason Curtis, the Company''s Senior Vice President, Finance and Accounting, served as Interim CFO since April 24, 2026. M.
- 2026-08-09 U.S. Physical Therapy Q2 Earnings Call Highlights U.S. Physical Therapy NYSE: USPH reported second-quarter 2026 revenue growth supported by higher patient volumes, improved reimbursement rates and the early rollout of hospital-affiliation agreements, while elevated employee healthcare claims and upfront staffing costs pressured physical therapy margins.
- 2026-08-07 U.S. Physical Therapy, Inc. (USPH) Q2 2026 Earnings Call Transcript U.S. Physical Therapy, Inc. (USPH) Q2 2026 Earnings Call Transcript
- 2026-08-06 U.S. Physical Therapy Continues To Heal U.S. Physical Therapy, Inc. remains rated Hold as operational growth is offset by disappointing profitability and fair valuation. USPH exceeded revenue expectations in Q2 2026, but EPS fell short due to one-time events and rising costs. Clinic expansion, hospital affiliations, and industrial injury prevention services are driving top-line growth and future margin improvement.